Alpha-1 Antitrypsin Deficiency Awareness

Team info
Description	Alpha-1 Antitrypsin Deficiency (AATD) — A Plain-Language Overview What it is Alpha-1 antitrypsin deficiency is a genetic condition where the body doesn't produce enough of a protein called alpha-1 antitrypsin (AAT). This protein is made mainly in the liver and normally travels through the bloodstream to protect tissues — especially the lungs — from damage caused by an enzyme called neutrophil elastase, which the immune system releases when fighting infection or inflammation. Without enough functioning AAT, that enzyme goes unchecked and starts breaking down healthy tissue. What causes it AATD is inherited — it's caused by mutations in the SERPINA1 gene, which contains the instructions for making the AAT protein. People inherit one copy of this gene from each parent. The most common "normal" version is called M. Certain variants, most notably Z and S, produce a version of the protein that's either deficient in quantity or misfolded. People with two normal copies (MM) are unaffected. People with one normal and one abnormal copy (like MZ) are carriers, usually with mild or no symptoms. People with two copies of the Z variant (PiZZ) have the most severe and clinically significant form. This genotype typically results in AAT blood levels far below the threshold needed to protect the lungs. How it impacts the body AATD affects people in two main ways, which can occur separately or together: Lungs: Without enough AAT circulating to restrain elastase, lung tissue — particularly the elastic fibers in the alveoli — gets progressively damaged. This leads to early-onset emphysema or COPD, often showing up in the 30s–50s, especially in smokers, though non-smokers can be affected too. Symptoms include shortness of breath, wheezing, and reduced exercise tolerance. Liver: This is a different mechanism — it's not about the lack of protective protein in the lungs, but about the misfolded Z-variant protein getting stuck inside liver cells instead of being released into the bloodstream. This buildup can trigger liver inflammation, fibrosis, and over time, cirrhosis. This is why PiZZ individuals face a real risk of liver disease independent of any lung involvement. Living with it Impact varies a lot by genotype, environmental exposures (especially smoking), and age at diagnosis. Management can include: Avoiding smoking and airway irritants Lung function monitoring (spirometry) and pulmonary care Liver monitoring — imaging, bloodwork, fibrosis staging (FibroScan, biopsy when needed) In eligible lung-affected patients, IV augmentation therapy (replacing AAT protein) can slow lung damage — though this doesn't treat the liver disease In advanced cases, either lung or liver transplantation may eventually be considered Because it's genetic, family members are often encouraged to get tested once one person is diagnosed, since AATD is under-recognized and frequently misdiagnosed as asthma or regular COPD for years before the right test — usually an AAT blood level plus genotyping — is done.
Created	11 Jul 2026
Web site	http://alpha1.org
Total credit	130
Recent average credit	4
14e credit	0 total, 0.00 average (0 tasks)
15e_small credit	0 total, 0.00 average (0 tasks)
15e credit	0 total, 0.00 average (0 tasks)
16e_small credit	0 total, 0.00 average (0 tasks)
16e credit	130 total, 3.84 average (1 tasks)
Cross-project stats	BOINCstats.com SETIBZH Free-DC
Country	International
Type	Unclassified
Members
Founder	Cthulhu
New members in last day	0
Total members	1 (view)
Active members	0 (view)
Members with credit	1 (view)